METiS TechBio (剂泰科技)

Hong Kong-listed AI nano-delivery company (7666.HK): AI-designed lipids and formulations, licensed to pharma and used in its own pipeline.

1. Core Product / Service

METiS was founded in 2020; its Hangzhou operating entity was registered in January 2020 [6]. Its core platform, NanoForge, combines a self-generated library of more than 10 million lipids with AI lipid-generation models, agents and a high-throughput experimental loop. Per the prospectus, the platform has accumulated about 100,000 experimental data points [1]. Three solutions sit on top of it:

• AiTEM: small-molecule formulation.
• AiLNP: nucleic-acid delivery.
• AiRNA: mRNA sequence design.

The company claims targeted formulations in two to three months and delivery to eight organs or tissues [1][2].

Pipeline. More than 10 products: four preclinical, three clinical-stage, one pre-NDA, and two animal-health programs [1].

• MTS-004. An orally disintegrating tablet of dextromethorphan plus quinidine for pseudobulbar affect. It met its Phase III primary endpoint in October 2025 [1].
• MTS-105. An mRNA-encoded T-cell engager for liver cancer and liver metastases, in an investigator-initiated trial, with FDA orphan designation [1][2].
• MTS-201. An oral TGR5 agonist in Phase I [1].

Wet-lab model: built in-house, with CRO support. METiS is the only company in its cohort with prospectus-level disclosure [1]:

• R&D centers in Beijing, Hangzhou and Cambridge, Massachusetts.
• More than 100 scientists and technical staff, including about 40 PhDs; over 70% of employees work in R&D.
• The prospectus lists R&D costs as including lab materials, equipment, and professional service fees paid to CROs.

Lab floor area is not disclosed.

2. Target Users & Pain Points

• Pharma and biotech partners that need delivery outside the liver for RNA and gene medicines, or better formulations for small molecules. METiS reports more than 30 partners. Since July 2025 it has signed five research collaborations valued at about US$45–109M per target [1]. AiTEM has been deployed on-site at Hengrui [2].
• Its own pipeline. The fastest asset is a reformulation that de-risks the chemistry, rather than a new molecule.

3. Competitive Landscape

4. Unique Observations

• "AI-native company" does not mean "AI-discovered drug" here. MTS-004 combines two approved drugs in a new dosage form. The novelty is in the delivery and formulation engine, not in target or molecule discovery.
• Revenue is deal-driven. 2025 revenue of RMB 105M came mainly from the MTS-004 upfront payment [2][4]. Gross margin jumped to 98% for the same reason [1].
• Listing produced the best wet-lab disclosure in the cohort. Most private Chinese AI-native peers publish only phrases like "high-throughput platform". METiS's prospectus gives staffing, sites and the explicit CRO line item.

5. Financials / Funding

• Total raised before the IPO: more than US$300M across eight rounds [1][2].
• Financials.
  • Revenue: RMB 9.3M (2023), RMB 1.5M (2024, one report says RMB 15M), RMB 105M (2025) [1][2].
  • Annual R&D spend: about RMB 270–290M [2].
  • Cash and financial assets: RMB 1.13B at end-2025 [1].
• MTS-004 China license (September 2025): RMB 100M upfront to Zhejiang Yin'an Pharma. Reported milestones differ: RMB 845M plus RMB 100M in one report, up to RMB 1.845B in others [1][2][4].

6. People & Relationships

• Co-founder & CEO: 赖才达 (Chris Lai), MIT PhD, formerly at McKinsey [1].
• Co-founder & Chief R&D Officer: 陈红明 (Hongming Chen), member of the US National Academy of Engineering, former CSO of Kala Pharmaceuticals [1].
• Co-founder & COO: Wang Wenshou, formerly at MIT CSAIL [1].
• Investors: HongShan, 5Y Capital, Lightspeed China, CICC Capital, PICC Capital, and xtalpi (an early investor).
• Peers: helixon-therapeutics, syneron-bio, mindrank, stonewise.

Sources

1. KrASIA (prospectus summary) — https://www.kr-asia.com/metis-techbio-clears-key-listing-hurdle-with-ai-nanodelivery-focus
2. CLS (financials and rounds) — https://www.cls.cn/detail/2370528
3. Tencent News (IPO and cornerstones) — https://news.qq.com/rain/a/20260506A03E1200
4. Lanjing — https://www.lanjinger.com/d/1778491446443107607
5. O'Melveny — https://www.omm.com/zh/news/press-releases/o-melveny-advises-on-first-ipo-of-an-ai-nano-delivery-company-in-us-270-million-hong-kong-chapter-18c-listing-of-metis-techbio/
6. Pharnexcloud company profile — https://www.pharnexcloud.com/qiye/hangzhoujitaiyiyaokejiyouxianzerengongsi